読み込み中
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
前日終値
$1.74
+$0.06 · +3.57%
日中の時刻はETです。市場データは遅延する場合があります。
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
日中レンジ
現在 $1.74
52週レンジ
現在 $1.74
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
41
適正価値
センチメント
58
まちまち
リスク
66
高リスク
モメンタム
17
強い下落
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
日中レンジ
現在 $1.74
52週レンジ
現在 $1.74
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 研究開発 | 681.9万 USD | 376.8万 USD | 323.2万 USD | 24.2万 USD | 24.9万 USD |
| 販売・一般管理 | 515.8万 USD | 446.7万 USD | 815.5万 USD | 199.7万 USD | 81.3万 USD |
| 営業費用 | 1197.7万 USD | 823.5万 USD | 1138.7万 USD | 223.9万 USD | 106.2万 USD |
| 受取利息 | 2.1万 USD | 2.5万 USD | — | — | — |
| 支払利息 | — | — | 208.2万 USD | 65.3万 USD | 54.7万 USD |
| 減価償却費と償却費 | 4000 USD | 4000 USD | 4000 USD | 3000 USD | 7.3万 USD |
| 営業利益 | −1197.7万 USD | −823.5万 USD | −1138.7万 USD | −223.9万 USD | −106.2万 USD |
| 純利益 | −1195.6万 USD | −820.7万 USD | −1303.7万 USD | −321.7万 USD | −155.9万 USD |
会社概要が更新されました 2026年10月11日.
この株式へのエクスポージャーを報告している上場投資信託です。
State Street SPDR Dow Jones Global Real Estate ETFRWO103.72万0.09%11.83億 USD0.50%$46.28+0.52%
State Street SPDR Dow Jones International Real Estate ETFRWX80.35万0.34%2.39億 USD0.59%$25.215+0.82%
State Street SPDR S&P International Small Cap ETFGWX32.83万0.04%9.08億 USD0.40%$45.56+0.93%
State Street SPDR Portfolio Europe ETFSPEU5.93万0.01%6.83億 USD0.07%$53.13+0.68%
Vanguard Extended Market ETFVXF4.1万0.00%954億 USD0.05%$235+0.80%State Street SPDR Dow Jones Global Real Estate ETFRWOState Street SPDR Dow Jones International Real Estate ETFRWXState Street SPDR S&P International Small Cap ETFGWXState Street SPDR Portfolio Europe ETFSPEUVanguard Extended Market ETFVXFAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
